Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

80.85USD
15 Feb 2019
Change (% chg)

$0.33 (+0.41%)
Prev Close
$80.52
Open
$81.14
Day's High
$81.65
Day's Low
$80.17
Volume
1,662,202
Avg. Vol
1,902,843
52-wk High
$122.00
52-wk Low
$75.77

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $121,615.90
Shares Outstanding(Mil.): 1,504.22
Dividend: 1.07
Yield (%): 5.29

Financials

  ABBV.N Industry Sector
P/E (TTM): 21.74 32.52 35.99
EPS (TTM): 3.72 -- --
ROI: -- 13.14 12.72
ROE: -- 14.13 13.73

AbbVie expects steeper decline in Humira's overseas sales; shares fall

AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent.

Jan 25 2019

UPDATE 3-AbbVie expects steeper decline in Humira's overseas sales; shares fall

Jan 25 AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent.

Jan 25 2019

AbbVie not contemplating big deals - CEO

Jan 25 AbbVie Inc is not considering a big merger or an acquisition, Chief Executive Officer Richard Gonzalez said on Friday, allaying speculations of the company launching a bid for Bristol-Myers Squibb.

Jan 25 2019

AbbVie profit misses as Humira faces biosimilar challenge in Europe

Jan 25 AbbVie Inc on Friday posted a fourth-quarter profit that missed Wall Street estimates, as the drugmaker's top-selling drug, Humira, faces competition from cheaper rival versions in Europe.

Jan 25 2019

AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

Jan 18 2019

UPDATE 1-AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

Jan 18 AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

Jan 18 2019

AbbVie's cancer drug fails to meet main goal in late-stage study

Jan 18 AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

Jan 18 2019

Abbvie to record $4 billion impairment charges on Stemcentrx assets

Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.

Jan 04 2019

Abbvie to record $4 bln impairment charges on Stemcentrx assets

Jan 4 Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.

Jan 04 2019

Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial.

Dec 17 2018

Earnings vs. Estimates